Article
#ESMO20: Bristol Myers marks Opdivo's second adjuvant win — eyeing a standard of care gap
Rating:
0.0
Views:
82
Likes:
1
Library:
1
Moving into earlier and earlier treatment lines, Bristol Myers Squibb is reporting that adjuvant treatment with Opdivo has doubled the time that esophageal or gastroesophageal junction cancer patients stay free of disease. With the CheckMate-577 data at ESMO, CMO Samit Hirawat said, the company believes it can change the treatment
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value